CTLA4 and malignant conjunctival melanoma: However, case reports showing responses to immune checkpoint inhibition, including responses to anti-CTLA4 monotherapy, anti-PD1 monotherapy, and combined anti-PD1/anti-CTLA4 therapy, support this treatment option in conjunctival melanoma [90,91].